Showing results (41-50 of 48) with videos related to
Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 48 results.
The Oncologist|July 2, 2013
Health-related quality of life with adjuvant docetaxel- and trastuzumab-based regimens in patients with node-positive and high-risk node-negative, HER2-positive early breast cancer: results from the BCIRG 006 StudyHeather-Jane Au, Wolfgang Eiermann, Nicholas J Robert, et al.Breast (Edinburgh, Scotland)|April 26, 2021
A multi-centre study comparing granulocyte-colony stimulating factors to antibiotics for primary prophylaxis of docetaxel-cyclophosphamide induced febrile neutropeniaMark Clemons, Dean Fergusson, Anil A Joy, et al.The New England Journal of Medicine|October 14, 2011
Adjuvant trastuzumab in HER2-positive breast cancerDennis Slamon, Wolfgang Eiermann, Nicholas Robert, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 17, 2012
Analysis of Fcγ receptor IIIa and IIa polymorphisms: lack of correlation with outcome in trastuzumab-treated breast cancer patientsSara A Hurvitz, David J Betting, Howard M Stern, et al.The Lancet. Oncology|August 13, 2013
Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trialDavid Cameron, Julia Brown, Rebecca Dent, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 22, 2024
Phase Ib Pharmacodynamic Study of the MNK Inhibitor Tomivosertib (eFT508) Combined With Paclitaxel in Patients With Refractory Metastatic Breast CancerCristiano Ferrario, John Mackey, Karen A Gelmon, et al.The New England Journal of Medicine|June 3, 2005
Adjuvant docetaxel for node-positive breast cancerMiguel Martin, Tadeusz Pienkowski, John Mackey, et al.Nature|April 13, 2012
The clonal and mutational evolution spectrum of primary triple-negative breast cancersSohrab P Shah, Andrew Roth, Rodrigo Goya, et al.Pageof 5